Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Dose-Ranging, Double Blind Study of Lidocaine Hydrochloride and/or Hydrocortisone Acetate (Alone or in Combination) in the 14-Day Twice-Daily Treatment of Grade I or II Hemorrhoids

Trial Profile

A Randomized, Dose-Ranging, Double Blind Study of Lidocaine Hydrochloride and/or Hydrocortisone Acetate (Alone or in Combination) in the 14-Day Twice-Daily Treatment of Grade I or II Hemorrhoids

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hydrocortisone (Primary) ; Lidocaine (Primary) ; Lidocaine/hydrocortisone (Primary)
  • Indications Haemorrhoids
  • Focus Therapeutic Use
  • Sponsors Citius Pharmaceuticals LLC
  • Most Recent Events

    • 06 Mar 2018 According to a Citius Pharmaceuticals media release, the company held a Type C meeting with the FDA to discuss the results of the Phase 2a study and to obtain the Agencys view on development plans to support the potential formulation change for the planned Phase 2b study.
    • 04 Feb 2016 New trial record
    • 01 Feb 2016 According to a Citius Pharmaceuticals media release, the company announced results of phase IIa trial of Hydrocortisone and Lidocaine combination cream in patients with grade I and II Hemorrhoids.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top